IL317183A - Combinations of rxfp1 modulators and sglt2 inhibitors - Google Patents
Combinations of rxfp1 modulators and sglt2 inhibitorsInfo
- Publication number
- IL317183A IL317183A IL317183A IL31718324A IL317183A IL 317183 A IL317183 A IL 317183A IL 317183 A IL317183 A IL 317183A IL 31718324 A IL31718324 A IL 31718324A IL 317183 A IL317183 A IL 317183A
- Authority
- IL
- Israel
- Prior art keywords
- rxfp1
- modulators
- combinations
- sglt2 inhibitors
- sglt2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263365969P | 2022-06-07 | 2022-06-07 | |
| PCT/EP2023/065046 WO2023237512A1 (en) | 2022-06-07 | 2023-06-06 | Combinations of rxfp1 modulators and sglt2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317183A true IL317183A (en) | 2025-01-01 |
Family
ID=86861850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317183A IL317183A (en) | 2022-06-07 | 2023-06-06 | Combinations of rxfp1 modulators and sglt2 inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20260069559A1 (en) |
| EP (1) | EP4536207A1 (en) |
| JP (1) | JP2025519439A (en) |
| KR (1) | KR20250020503A (en) |
| CN (1) | CN119325376A (en) |
| AU (1) | AU2023284027A1 (en) |
| CA (1) | CA3257184A1 (en) |
| IL (1) | IL317183A (en) |
| MX (1) | MX2024015074A (en) |
| TW (1) | TW202415364A (en) |
| WO (1) | WO2023237512A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260116187A (en) * | 2023-11-17 | 2026-07-28 | 일라이 릴리 앤드 캄파니 | RXFP1 receptor agonist |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| US9452973B2 (en) | 2012-05-04 | 2016-09-27 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Modulators of the relaxin receptor 1 |
| AU2021395353B2 (en) * | 2020-12-08 | 2024-08-29 | Astrazeneca Ab | 4-(2-fluoro-4-methoxy-5-3-(((1-methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)phenoxy)-1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as rxfp1 modulators for the treatment of heart failure |
-
2023
- 2023-06-06 CN CN202380044989.3A patent/CN119325376A/en active Pending
- 2023-06-06 CA CA3257184A patent/CA3257184A1/en active Pending
- 2023-06-06 MX MX2024015074A patent/MX2024015074A/en unknown
- 2023-06-06 US US18/872,319 patent/US20260069559A1/en active Pending
- 2023-06-06 TW TW112121132A patent/TW202415364A/en unknown
- 2023-06-06 KR KR1020247042966A patent/KR20250020503A/en active Pending
- 2023-06-06 WO PCT/EP2023/065046 patent/WO2023237512A1/en not_active Ceased
- 2023-06-06 JP JP2024571872A patent/JP2025519439A/en active Pending
- 2023-06-06 EP EP23732002.3A patent/EP4536207A1/en active Pending
- 2023-06-06 AU AU2023284027A patent/AU2023284027A1/en active Pending
- 2023-06-06 IL IL317183A patent/IL317183A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250020503A (en) | 2025-02-11 |
| JP2025519439A (en) | 2025-06-26 |
| CA3257184A1 (en) | 2023-12-14 |
| US20260069559A1 (en) | 2026-03-12 |
| TW202415364A (en) | 2024-04-16 |
| CN119325376A (en) | 2025-01-17 |
| AU2023284027A1 (en) | 2025-01-23 |
| WO2023237512A1 (en) | 2023-12-14 |
| EP4536207A1 (en) | 2025-04-16 |
| MX2024015074A (en) | 2025-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4093385A4 (en) | Pgdh inhibitors and methods of making and using | |
| EP4143196A4 (en) | PI3K-a INHIBITORS AND METHODS OF USE THEREOF | |
| IL321357A (en) | Inhibitors of kif18a and uses thereof | |
| IL317543A (en) | Kinase modulators and methods of use thereof | |
| CA3264917A1 (en) | Inhibitors of kif18a and uses thereof | |
| IL312466A (en) | Pi3k-alpha inhibitors and methods of making and using the same | |
| EP4341254A4 (en) | Inhibitors and degraders of pip4k protein | |
| EP4329735A4 (en) | Kcnt1 inhibitors and methods of use | |
| IL317288A (en) | Inhibitors of expression and/or function | |
| EP4025197A4 (en) | Inhibitors of sglt and uses thereof | |
| IL321255A (en) | Adar1 inhibitors and methods of using the same | |
| HK40127096A (en) | Combinations of rxfp1 modulators and sglt2 inhibitors | |
| EP4119164A4 (en) | Anti-coronavirus effect and application of pi4k inhibitor | |
| AU2024397820A1 (en) | Vps34 inhibitors and methods of use thereof | |
| IL325863A (en) | Inhibitors of expression and/or function | |
| HK40107819A (en) | Wdr5 inhibitors and modulators | |
| GB202208124D0 (en) | Inhibitors of expression and/or function | |
| GB202208122D0 (en) | Inhibitors of expression and/or function | |
| HK40101141A (en) | Gpr52 modulators and methods of use | |
| CA3275344A1 (en) | Adar1 inhibitors and methods of using the same | |
| HK40082392A (en) | Gpr52 modulators and methods of use | |
| CA3299172A1 (en) | Inhibitors of expression and/or function | |
| CA3293419A1 (en) | Inhibitors of expression and/or function | |
| HK40108854A (en) | Kcnt1 inhibitors and methods of use | |
| HK40120757A (en) | T-type calcium channel modulators comprising an azaspiroheptane core and methods of use thereof |